Experimental cell therapy takes on COVID-19 lung crisis
NCT ID NCT04582201
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested a new cell therapy called agenT-797 in 20 hospitalized COVID-19 patients with moderate to severe breathing distress. The therapy uses immune cells from a healthy donor to calm inflammation and fight the virus. The main goals were to check safety and side effects, with additional measures like time on a ventilator and survival rates.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- agenT-797 (a type of immune cell therapy made from donor cells)
- What this could lead to
- If successful, this could point toward a new treatment option for severe respiratory distress caused by COVID-19.
- What could go wrong
- This is a very early Phase 1 trial with only 20 participants, so results may not apply broadly. The therapy involves donor cells, which could cause immune reactions or other side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE RESPIRATORY DISTRESS SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Norton Cancer Institute, St. Matthews Campus
Louisville, Kentucky, 40207, United States
-
Saint John's Cancer Institute
Santa Monica, California, 90404, United States
-
Weill Cornell Medicine New York Presbyterian
New York, New York, 10022, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Brain fog after COVID: can two common drugs clear it?
- Could a five-day pill course cut COVID-19 deaths? czech nationwide data puts molnupiravir to the test.
- Can COVID-19 and emergency surgery be safely managed together? a massive hospital study seeks answers
- Text or call? study tests best way to boost COVID shots in schools
- Fish oil and Body's own healing molecules could lift long COVID depression
- 13,000 volunteers shed light on who gets sick from COVID-19